EP3494217A4 - Lmp1-expressing cells and methods of use thereof - Google Patents
Lmp1-expressing cells and methods of use thereof Download PDFInfo
- Publication number
- EP3494217A4 EP3494217A4 EP17837602.6A EP17837602A EP3494217A4 EP 3494217 A4 EP3494217 A4 EP 3494217A4 EP 17837602 A EP17837602 A EP 17837602A EP 3494217 A4 EP3494217 A4 EP 3494217A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lmp1
- methods
- expressing cells
- expressing
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Husbandry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370011P | 2016-08-02 | 2016-08-02 | |
US201762506281P | 2017-05-15 | 2017-05-15 | |
US201762532622P | 2017-07-14 | 2017-07-14 | |
PCT/US2017/045089 WO2018026911A1 (en) | 2016-08-02 | 2017-08-02 | Lmp1-expressing cells and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3494217A1 EP3494217A1 (en) | 2019-06-12 |
EP3494217A4 true EP3494217A4 (en) | 2020-01-01 |
Family
ID=61073082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17837602.6A Pending EP3494217A4 (en) | 2016-08-02 | 2017-08-02 | Lmp1-expressing cells and methods of use thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US11369635B2 (en) |
EP (1) | EP3494217A4 (en) |
CN (1) | CN109477092A (en) |
AU (1) | AU2017306301B2 (en) |
CA (1) | CA3031725A1 (en) |
WO (1) | WO2018026911A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020006098A2 (en) * | 2018-06-26 | 2020-01-02 | Children's National Medical Center | Tumor-associated markers for detection of minimal residual disease using digital droplet pcr |
CA3106980A1 (en) * | 2018-07-22 | 2020-01-30 | Health Research, Inc. | Major histocompatibility complex class ll-expressing cancer cell vaccine and methods of use for producing integrated immune responses |
CA3131777A1 (en) * | 2019-03-01 | 2020-09-10 | Flow Pharma Inc. | Design, manufacture, and use of personalized cancer vaccines |
CN112390860A (en) * | 2020-11-12 | 2021-02-23 | 天津大学 | EB virus epitope and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196389A1 (en) * | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
WO2007131182A2 (en) * | 2006-05-04 | 2007-11-15 | Board Of Regents Of The University Of Nebraska | System for high production of natural and personalized interferons |
DE102014001771A1 (en) * | 2014-02-09 | 2015-08-13 | Mannalabs Gbr (Vertretungsberechtigter Gesellschafter: Dr. Dr. Rüdiger Marcus Flaig, 82223 Eichenau) | Optimized pseudovirions (Ω-virions) as a basis for vaccines and individualized tumor therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102177177A (en) | 2008-08-08 | 2011-09-07 | 国家科学研究中心 | Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1) |
-
2017
- 2017-08-02 CN CN201780043095.7A patent/CN109477092A/en active Pending
- 2017-08-02 CA CA3031725A patent/CA3031725A1/en active Pending
- 2017-08-02 US US16/322,812 patent/US11369635B2/en active Active
- 2017-08-02 EP EP17837602.6A patent/EP3494217A4/en active Pending
- 2017-08-02 AU AU2017306301A patent/AU2017306301B2/en active Active
- 2017-08-02 WO PCT/US2017/045089 patent/WO2018026911A1/en unknown
-
2022
- 2022-05-13 US US17/663,344 patent/US20220362296A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196389A1 (en) * | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
WO2007131182A2 (en) * | 2006-05-04 | 2007-11-15 | Board Of Regents Of The University Of Nebraska | System for high production of natural and personalized interferons |
DE102014001771A1 (en) * | 2014-02-09 | 2015-08-13 | Mannalabs Gbr (Vertretungsberechtigter Gesellschafter: Dr. Dr. Rüdiger Marcus Flaig, 82223 Eichenau) | Optimized pseudovirions (Ω-virions) as a basis for vaccines and individualized tumor therapy |
Non-Patent Citations (1)
Title |
---|
See also references of WO2018026911A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA3031725A1 (en) | 2018-02-08 |
US11369635B2 (en) | 2022-06-28 |
AU2017306301B2 (en) | 2023-12-07 |
AU2017306301A1 (en) | 2019-01-24 |
US20220362296A1 (en) | 2022-11-17 |
WO2018026911A1 (en) | 2018-02-08 |
US20190192572A1 (en) | 2019-06-27 |
EP3494217A1 (en) | 2019-06-12 |
CN109477092A (en) | 2019-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3500355A4 (en) | Bioreactor and methods of use thereof | |
EP3436048A4 (en) | Neoantigens and methods of their use | |
HK1250481A1 (en) | Modified t cells and methods of making and using the same | |
EP3429635A4 (en) | Anti-crispr compounds and methods of use | |
EP3328399A4 (en) | Modified cells and methods of therapy | |
EP3504213A4 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
EP3601528A4 (en) | Cells and methods of uses and making the same | |
EP3568467A4 (en) | Modified t cells and methods of their use | |
EP3383430A4 (en) | Antibodies and methods of use thereof | |
EP3245291A4 (en) | Novel micro-dystrophins and related methods of use | |
EP3303634A4 (en) | Cas9 variants and methods of use thereof | |
EP3548033A4 (en) | Compounds and their methods of use | |
EP3280441A4 (en) | Anti-sortilin antibodies and methods of use thereof | |
EP3149025A4 (en) | Cell penetrating peptides and methods of making and using thereof | |
EP3377070A4 (en) | Compounds and methods of their use | |
EP3125960A4 (en) | Click-crosslinked hydrogels and methods of use | |
EP3509615A4 (en) | Stable peptides and methods of use thereof | |
EP3319611A4 (en) | Oxysterols and methods of use thereof | |
EP3231024A4 (en) | Electrochemical cell and method of making the same | |
EP3319610A4 (en) | Oxysterols and methods of use thereof | |
EP3319612A4 (en) | Oxysterols and methods of use thereof | |
EP3157528A4 (en) | Oxysterols and methods of use thereof | |
EP3373969A4 (en) | Glycan-interacting compounds and methods of use | |
EP3436022A4 (en) | Oxysterols and methods of use thereof | |
EP3240576A4 (en) | Methods of transdifferentiation and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190227 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/005 20060101ALN20191127BHEP Ipc: C12N 15/66 20060101ALI20191127BHEP Ipc: C12N 15/09 20060101AFI20191127BHEP Ipc: C12N 15/86 20060101ALI20191127BHEP Ipc: C12N 15/63 20060101ALI20191127BHEP Ipc: C12N 15/79 20060101ALI20191127BHEP Ipc: C07K 14/05 20060101ALI20191127BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008188 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230413 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |